Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Pinter

Showing results (91-100 of 135) with videos related to

Pageof 14
Sort By:
Advances in Therapy|December 14, 2022
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World SettingCharles Lynde, Elisabeth Riedl, Julia-Tatjana Maul, et al.
Journal of the American Academy of Dermatology|September 25, 2016
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR studyAndrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, et al.
American Journal of Clinical Dermatology|July 20, 2022
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc AnalysisJonathan I Silverberg, David N Adam, Matthew Zirwas, et al.
Dermatology and Therapy|July 11, 2025
Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment ComparisonSonja Ständer, Andreas Pinter, Firas G Hougeir, et al.
Dermatology and Therapy|December 29, 2025
A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'"Sonja Ständer, Andreas Pinter, Firas G Hougeir, et al.
Rheumatology and Therapy|April 25, 2024
Elevating the Standard of Care for Patients with Psoriatic Arthritis: 'Calls to Action' from a Multistakeholder Pan-European InitiativeIris Verbinnen, Emilio Monte-Boquet, Detlev Parow, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 22, 2022
A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30<sup>th</sup> EADV Congress 2021Andreas Pinter, Linda Stein Gold, Adam Reich, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 17, 2022
Generalisierte pustulöse Psoriasis: Überblick zum Status quo und Ergebnisse einer DiskussionsrundeKristian Reich, Matthias Augustin, Sascha Gerdes, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 8, 2022
Generalized pustular psoriasis: overview of the status quo and results of a panel discussionKristian Reich, Matthias Augustin, Sascha Gerdes, et al.
Journal of the American Academy of Dermatology|August 11, 2019
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR studyDiamant Thaçi, Lluís Puig, Kristian Reich, et al.
Pageof 14

Showing results (91-100 of 135) with videos related to

Sort By:
Pageof 14
Advances in Therapy|December 14, 2022
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World SettingCharles Lynde, Elisabeth Riedl, Julia-Tatjana Maul, et al.
Journal of the American Academy of Dermatology|September 25, 2016
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR studyAndrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, et al.
American Journal of Clinical Dermatology|July 20, 2022
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc AnalysisJonathan I Silverberg, David N Adam, Matthew Zirwas, et al.
Dermatology and Therapy|July 11, 2025
Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment ComparisonSonja Ständer, Andreas Pinter, Firas G Hougeir, et al.
Dermatology and Therapy|December 29, 2025
A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'"Sonja Ständer, Andreas Pinter, Firas G Hougeir, et al.
Rheumatology and Therapy|April 25, 2024
Elevating the Standard of Care for Patients with Psoriatic Arthritis: 'Calls to Action' from a Multistakeholder Pan-European InitiativeIris Verbinnen, Emilio Monte-Boquet, Detlev Parow, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 22, 2022
A novel, fixed-dose calcipotriol and betamethasone dipropionate cream for the topical treatment of plaque psoriasis: Direct and indirect evidence from phase 3 trials discussed at the 30<sup>th</sup> EADV Congress 2021Andreas Pinter, Linda Stein Gold, Adam Reich, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 17, 2022
Generalisierte pustulöse Psoriasis: Überblick zum Status quo und Ergebnisse einer DiskussionsrundeKristian Reich, Matthias Augustin, Sascha Gerdes, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 8, 2022
Generalized pustular psoriasis: overview of the status quo and results of a panel discussionKristian Reich, Matthias Augustin, Sascha Gerdes, et al.
Journal of the American Academy of Dermatology|August 11, 2019
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR studyDiamant Thaçi, Lluís Puig, Kristian Reich, et al.
Pageof 14